Clinical Trial

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-29
Trial Details
NCT Number NCT07303777
Lead Sponsor Atom Therapeutics Co., Ltd
Conditions Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Enrollment 200 participants
Start Date 2026-04-23
Primary Completion 2028-01 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-28